Kari Ferver
Overview
Kari effectively represents clients in complex and fast-paced antitrust and litigation matters, particularly in the healthcare space. She works closely with clients and colleagues to assess difficult and novel legal issues and craft associated strategies. Kari regularly drafts substantive motions and complaints; prepares corporate representatives for depositions; and communicates with clients about litigation developments and industry updates.
Career & Education
- University of California, Irvine, B.A., summa cum laude, Criminology, Law & Society, 2006
- University of California, Irvine, M.A., Social Ecology, 2009
- University of California, Irvine School of Law, J.D., summa cum laude, 2021
- California
Kari's Insights
Client Alert | 4 min read | 05.07.24
The Food and Drug Administration (FDA) has published revised draft guidelines in the Federal Register on promotional labeling and advertising considerations for the biologic and biosimilar industry, updating guidance from 2020. The quick revisions emphasize the fast-changing and rapidly growing nature of this industry.
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
Blog Post | 04.23.24
Blog Post | 02.07.24
Kari's Insights
Client Alert | 4 min read | 05.07.24
The Food and Drug Administration (FDA) has published revised draft guidelines in the Federal Register on promotional labeling and advertising considerations for the biologic and biosimilar industry, updating guidance from 2020. The quick revisions emphasize the fast-changing and rapidly growing nature of this industry.
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
Blog Post | 04.23.24
Blog Post | 02.07.24